IBL News

Any IBL product introduced in this IBL news is applicable for research use only and it cannot be used for diagnosis or medical purpose.

We introduce an article on a clinical trial of a novel siRNA antihypertensive drug targeting angiotensinogen (AGT), a precursor of the blood pressure-elevating peptide angiotensin II. The paper reports the results of a phase I trial (ClinicalTrials.gov No.: NCT03934307) of the siRNA antihypertensive drug Zilebesiran that enrolled 107 patients with hypertension.

Please refer to the following publication for more details.
The main points of this paper are summarized below.

1. )　No serious adverse events were reported. (Mild injection site reactions were observed in a few patients.)
2. )　Serum AGT levels decreased in correlation with Zilebesiran dosage.
3. )　Systolic and diastolic blood pressures decreased in correlation with serum AGT levels.
4. )　Blood pressures that decreased after Zilebesiran administration recovered to baseline after ingestion of a high-salt diet. A further slight decrease in blood pressures was observed after additional administration of Iversartan (angiotensin II receptor blocker).

 
The following IBL ELISA Kit was used in this paper.  
Hypertension is an important risk factor for ischemic heart disease, stroke, and chronic kidney disease.
Although various treatments with antihypertensive medications exist, almost half of hypertensive patients do not reach the target blood pressure levels recommended by guidelines because physicians do not prescribe appropriate medications or patients fail to take their daily oral medications. Thus, there remains a significant unmet need in the treatment of hypertension.
 
Zilebesiran is an antihypertensive drug with a novel mechanism that strongly suppresses AGT synthesis through hepatocyte-specific RNA interference. The results of this paper demonstrate that a single subcutaneous injection continuously decreases blood pressures for at least approximately 6 months, promising Zilebesiran as a next-generation antihypertensive drug.
 
The following four phase II trials of Zilebesiran are currently underway.

1. )　A monotherapy study (ClinicalTrials.gov Number: NCT04936035)
2. )　An add-on therapy study to existing antihypertensive drugs (NCT05103332)
3. )　A study in patients at high risk of cardiovascular events (NCT06272487)
4. )　A study in Japanese subjects (NCT06423352)

 
Of these, 1) a monotherapy study (NCT04936035) in 394 hypertensive patients demonstrated that a single 600 mg dose of Zilebesiran significantly decreased blood pressures for 6 months, the results of which were published in the following article.  
Our product #27412 Human Total Angiotensinogen Assay Kit - IBL is expected to be used in the ongoing phase II studies.
 
The #27412 Human Total Angiotensinogen Assay Kit - IBL has also been used in numerous basic research and clinical trials to measure AGT in urine to monitor RAS activity in the kidney.
 
IBL offers wide range of ELISA kits to measure AGT.

<Total Angiotensinogen Assay kit>
#27412 Human Total Angiotensinogen Assay Kit - IBL
#27103 Mouse Total Angiotensinogen Assay Kit - IBL
#27104 Rat Total Angiotensinogen Assay Kit - IBL

<Intact Angiotensinogen Assay kit>
#27742 Human Intact Angiotensinogen Assay Kit - IBL
#27105 Mouse Intact Angiotensinogen Assay Kit - IBL
#27106 Rat Intact Angiotensinogen Assay Kit - IBL
 
We hope you will find our products useful in your research activities.
 
Keyword: Angiotensinogen, AGT, AngiotensinII, Renin, Aldosterone, RAAS, siRNA, Hypertension
 
Please feel free to contact us.

Sales Department
Antibody related Business Division
Immuno-Biological Laboratories Co., Ltd.
Email: do-ibl@ibl-japan.co.jp



IBL-Japan (Specific Antibody Development) 30sec video

IBL-Japan (Specific Antibody Development) 2min video

LipoSEARCH® - Lipoprotein Analyzing Systems (Patented GP-HPLC Systems) 30sec video